ARID1A is altered in 4.24% of anal carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATM is altered in 4.48% of anal carcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATR is altered in 4.43% of anal carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ATRX is altered in 6.71% of anal carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BARD1 is altered in 1.52% of anal carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BARD1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRCA1 is altered in 7.1% of anal carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRCA2 is altered in 4.71% of anal carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRIP1 is altered in 3.14% of anal carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRIP1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains C11orf30 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CCNE1 is altered in 2.5% of anal carcinoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CDK12 is altered in 2.52% of anal carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CHEK1 is altered in 0.74% of anal carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CHEK2 is altered in 1.88% of anal carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHEK2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC2 is altered in 1.97% of anal carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC3 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC4 is altered in 1.37% of anal carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC4 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC5 is altered in 4.79% of anal carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC5 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC6 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCA is altered in 1.83% of anal carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCA status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCB status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCC is altered in 0.63% of anal carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCC status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCD2 is altered in 3.95% of anal carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCD2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCE status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCF status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCG status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCI is altered in 2.44% of anal carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCI status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCL status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCM is altered in 8.82% of anal carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FANCM status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM2 is altered in 0.62% of anal carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLH1 is altered in 2.06% of anal carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MLH3 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MRE11A is altered in 2.84% of anal carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MRE11A status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH2 is altered in 1.79% of anal carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MSH6 is altered in 3.03% of anal carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MUTYH is altered in 0.63% of anal carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MUTYH status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MYC is altered in 1.9% of anal carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NBN is altered in 1.92% of anal carcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NPM1 is altered in 1.8% of anal carcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PALB2 is altered in 4.19% of anal carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PALB2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PARP1 is altered in 2.25% of anal carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PMS1 is altered in 3.31% of anal carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PMS2 is altered in 1.96% of anal carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PMS2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

POLE is altered in 3.73% of anal carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PPP2R1A is altered in 0.68% of anal carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R1A status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R2A status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD50 is altered in 2.86% of anal carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51 is altered in 0.62% of anal carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51B status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51C status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD51D status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD54L status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RB1 is altered in 1.99% of anal carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

SLX4 is altered in 4.65% of anal carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SLX4 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

SMARCB1 is altered in 1.03% of anal carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

STAG2 is altered in 3.12% of anal carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

STK11 is altered in 8.96% of anal carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STK11 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

TP53 is altered in 10.5% of anal carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XRCC1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].